These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 14748000)

  • 1. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
    Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
    Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Madura JD
    Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT.
    Barreca ML; Rao A; De Luca L; Zappalà M; Monforte AM; Maga G; Pannecouque C; Balzarini J; De Clercq E; Chimirri A; Monforte P
    J Med Chem; 2005 May; 48(9):3433-7. PubMed ID: 15857150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
    Medina-Franco JL; Rodríguez-Morales S; Juárez-Gordiano C; Hernández-Campos A; Jiménez-Barbero J; Castillo R
    Bioorg Med Chem; 2004 Dec; 12(23):6085-95. PubMed ID: 15519154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
    García-Sosa AT; Sild S; Takkis K; Maran U
    J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
    Zhou Z; Madura JD
    Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a MIP-based alignment and docking in computer-aided drug design.
    Barbany M; Gutiérrez-de-Terán H; Sanz F; Villà-Freixa J
    Proteins; 2004 Aug; 56(3):585-94. PubMed ID: 15229890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
    Wang J; Kang X; Kuntz ID; Kollman PA
    J Med Chem; 2005 Apr; 48(7):2432-44. PubMed ID: 15801834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase.
    Carlsson J; Boukharta L; Aqvist J
    J Med Chem; 2008 May; 51(9):2648-56. PubMed ID: 18410085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
    Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAsDock: a new approach for rapid flexible docking based on an improved multi-population genetic algorithm.
    Li H; Li C; Gui C; Luo X; Chen K; Shen J; Wang X; Jiang H
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4671-6. PubMed ID: 15324886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining structure-based drug design and pharmacophores.
    Griffith R; Luu TT; Garner J; Keller PA
    J Mol Graph Model; 2005 Apr; 23(5):439-46. PubMed ID: 15781186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
    Ribone SR; Quevedo MA; Madrid M; Briñón MC
    J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
    Sengupta D; Verma D; Naik PK
    In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
    Li Z; Han J; Chen HF
    Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
    Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
    J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.